Avexa Of Australia Seeks Investors As Phase III Trials Of HIV Drug End
This article was originally published in PharmAsia News
Executive Summary
Australia's Avexa says it is inviting investors to help it develop an HIV drug about to complete Phase III studies. Avexa CEO Julian Chick acknowledged his firm, which has no approved products and has never made a profit, is discussing with people about providing it with additional funds. Data from the final studies of its apricitabine HIV drug still remain to be analyzed, but Avexa expects to announce the results within six months. (Click here for more
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.